Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Revenue (2016 - 2025)

Historic Revenue for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $452000.0.

  • Cartesian Therapeutics' Revenue rose 1679.59% to $452000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 9772.41%. This contributed to the annual value of $38.9 million for FY2024, which is 4964.24% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Revenue stood at $452000.0 for Q3 2025, which was up 1679.59% from $298000.0 recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Revenue high stood at $39.3 million for Q2 2022, and its period low was -$759000.0 during Q4 2024.
  • Its 5-year average for Revenue is $13.8 million, with a median of $8.3 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Cartesian Therapeutics' Revenue was 53716.9% (2024), while the steepest drop was 10918.22% (2024).
  • Cartesian Therapeutics' Revenue (Quarter) stood at $29.9 million in 2021, then tumbled by 43.9% to $16.8 million in 2022, then tumbled by 50.78% to $8.3 million in 2023, then crashed by 109.18% to -$759000.0 in 2024, then soared by 159.55% to $452000.0 in 2025.
  • Its last three reported values are $452000.0 in Q3 2025, $298000.0 for Q2 2025, and $1.1 million during Q1 2025.